Evidence record · ER-DSIP-INSOMNIA-022
Does DSIP improve chronic insomnia?
DSIP improves sleep in people with chronic insomnia
DSIP has small historic human sleep studies with inconsistent and generally modest findings. One controlled chronic-insomnia study found weak effects rather than a major therapeutic benefit, while other reports used different populations and outcomes. The evidence is mixed and too limited to support dependable self-treatment.
Claim boundary
What this verdict covers
The claim concerns clinically meaningful improvement in chronic insomnia, including sleep continuity and daytime function. A change in one sleep-stage measure is not enough.
- Compound
- DSIP or emideltide
- Population
- Adults with chronic insomnia
- Outcome
- Sleep duration, continuity or daytime function
- Record ID
- ER-DSIP-INSOMNIA-022
Evidence synthesis
What the research can support
Historic studies used small samples, varied protocols and different sleep outcomes. A double-blind study in 16 people with chronic insomnia reported only weak effects and no major therapeutic benefit, while other reports do not resolve the inconsistency.
Why the confidence is low
The literature is old, small and difficult to generalise to current diagnostic criteria or products. Safety and product-quality evidence are inadequate.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-DSIP-INSOMNIA-022 addresses one bounded question: Does DSIP improve chronic insomnia?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 4 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Unclear or conflicting, the verdict is Mixed and confidence is Low. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| Double-blind DSIP study in chronic insomnia | The small study reported weak effects rather than major therapeutic benefit. | Sixteen participants cannot provide a precise or generalisable estimate. | 10 August 2026 |
| Historic DSIP sleep study | The paper provides early human sleep observations. | Methods and outcomes differ from a modern insomnia treatment trial. | 10 August 2026 |
| DSIP clinical sleep report | The study adds another small and heterogeneous human result. | It does not resolve the conflicting evidence base. | 10 August 2026 |
| DSIP human research report | The paper documents further clinical investigation. | It does not establish durable benefit or modern product safety. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on DSIP or emideltide for this claim?
The verdict is mixed for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
Historic studies used small samples, varied protocols and different sleep outcomes. A double-blind study in 16 people with chronic insomnia reported only weak effects and no major therapeutic benefit, while other reports do not resolve the inconsistency. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is DSIP or emideltide authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Athletes should check the current WADA Prohibited List and obtain sport-specific advice. An experimental or non-approved peptide may fall within the S0 category even when it is not named individually. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What could change this verdict?
A modern preregistered randomised trial using current insomnia criteria, objective and patient-reported outcomes, adequate duration and transparent harm reporting. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation